The nuclear factor of activated T-cells (NFAT p ) is a phosphorylated transcription factor that resides in the cytoplasm of unactivated T-cells. T-cell activation results in the activation of the phosphatase calcineurin (CaN), which leads to the dephosphorylation and subsequent nuclear localization of NFAT p . We have investigated the role of kinases in the phosphorylation state and subcellular localization of NFAT p . The phosphorylation state and nuclear\cytoplasmic location of NFAT p were determined in unstimulated murine HT-2 cells treated with a panel of kinase inhibitors. Two of the seven kinase inhibitors, staurosporine (St) and bisindolylmaleimide I (BI), resulted in the dephosphorylation and nuclear localization of NFAT p . These Stinduced effects were inhibited by pretreatment with FK506,
INTRODUCTION
Antigen-induced T-cell activation results in the transcriptional activation of a variety of cytokine genes, including interleukin 2, interleukin 4 and colony-stimulating factor. Activation of these genes is mediated in part by nuclear factor of activated T-cells (NFAT), a DNA-binding protein that binds to specific sites on the regulatory regions of these genes (reviewed in [1, 2] ). Molecular cloning studies have demonstrated that at least four different NFAT genes exist, including NFAT p , NFAT c , NFAT3 and NFAT x , all of which contain a Rel homology region that is important for DNA binding [3] [4] [5] [6] . In addition, a serine\proline repeat region of unknown function is present in each of the family members, as well as a putative nuclear localization sequence. The exact biological function of each of the NFAT proteins is not known, although differences in cell and tissue expression, as well as DNA-binding activity, have been observed [3, 7, 8] .
Studies with the immunosuppressant drugs cyclosporin A (CsA) and FK506, which inhibit T-cell activation, have provided insight into the molecular mechanism of NFAT action. These drugs, when bound to their respective immunophilins, cyclophilin, and FKBP-12, inhibit the activity of calcineurin (CaN), a calmodulin-dependent phosphatase [9, 10] . The ability of a number of FK506 and CsA analogues to inhibit CaN phosphatase activity is correlated with their ability to inhibit T-cell activation, consistent with the hypothesis that CaN is a cellular target of the drugs. In addition, overexpression of a constitutively active form of CaN augments T-cell activation resulting from stimulation by both Ca# + and protein kinase C (PKC), suggesting that CaN has a key role in the physiological pathway of T-cell activation [11] [12] [13] .
Abbreviations used : BI, bisindolylmaleimide I ; CaN, calcineurin ; CsA, cyclosporin A ; NES, nuclear export sequence ; NLS, nuclear localization sequence ; NFAT p , nuclear factor of activated T-cells ; PKC, protein kinase C ; PKI, protein heat-stable inhibitor of cAMP-dependent kinase ; St, staurosporine.
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indicating that CaN activity was required for the observed effects on NFAT p . Treatment of cells with ionomycin resulted in NFAT p dephosphorylation and nuclear localization. Removal of ionomycin from the cells resulted in the reappearance of phosphorylated NFAT p in the cytosol. St and BI also inhibited the reaccumulation of NFAT p in the cytoplasm and its re-phosphorylation after ionomycin removal. The re-accumulation of NFAT p in the cytosol after ionomycin withdrawal was shown to be energy-and temperature-dependent. Taken together, these results suggest that in unstimulated cells NFAT p is actively maintained in the cytoplasm by kinases acting in opposition to basal CaN activity.
The link between CaN and NFAT p (also called NFATC2 [6] and NFAT1 [14] ) is provided by evidence demonstrating that NFAT p is a CaN substrate. Using immunocomplex assays we have shown that NFAT p is a direct CaN substrate in itro [15] . In addition, a direct association between CaN and NFAT p has been demonstrated with immobilized CaN bound to calmodulin-Sepharose, and the site of interaction on NFAT p has been mapped to the N-terminal 415 amino acid residues [14, 16] . In intact HT-2 cells we demonstrated directly, by using $#P-labelling experiments, that NFAT p is present in a phosphorylated state in the cytosol of unactivated T-cells. Furthermore, the activation of cells after treatment with ionomycin results in dephosphorylation of NFAT p that is inhibited by pretreatment with either CsA or FK506 [15, 17] .
The level of NFAT p phosphorylation in cells is dependent on CaN activity but, in addition, the phosphorylation state of NFAT p is a determinant of its localization within the cell. In our previous studies we demonstrated that ionomycin treatment of HT-2 cells results in the dephosphorylation and nuclear localization of NFAT p ; after the removal of ionomycin, NFAT p reappears in the cytosol in a phosphorylated form. Pretreatment of the cells with FK506 inhibits the ionomycin-induced NFAT p nuclear localization, and under these conditions NFAT p remains in the cytosol in a phosphorylated form [15] . Loh et al. [14] demonstrated similar results in immunofluorescence experiments, and in addition they showed that repeated cycles of ionomycin treatment followed by washout result in the successive phosphorylation and dephosphorylation of NFAT p .
In the studies reported here we have examined the conditions regulating NFAT p localization. We show that in unstimulated cells, treatment with the kinase inhibitors staurosporine (St) and bisindolylmaleimide I (BI) results in NFAT p dephosphorylation and nuclear localization. Furthermore, the reaccumulation of NFAT p into the cytosol, which normally occurs after ionomycin withdrawal, is also inhibited by treatment with St and BI. These results suggest a model in which a dynamic equilibrium exists between kinase(s) and CaN that determines the net phosphorylation state and subcellular location of NFAT p in resting as well as activated T-cells. 
MATERIALS AND METHODS

Materials
Cell culture
The murine helper T-cell line HT-2 was grown exactly as described [15] .
Cellular fractionation
Treatment of HT-2 cells (10' per condition) was performed as described in the Figure legends. Cells were washed in PBS and lysed in buffer (10 mM Tris\HCl, pH 7.5, containing 10 mM NaCl, 3 mM MgCl # , 1 mM PMSF, 0.5 mM dithiothreitol, 0.1 mM EGTA, 2 µM leupeptin, 1 µg\ml aprotinin and 0.05 % Nonidet P40) as described [15] . Lysed cells were centrifuged at 650 g to pellet the nuclei ; the supernatant was removed. The nuclear pellet was washed in lysis buffer without detergent, and the final pellet was resuspended in Laemmli buffer. The lowspeed supernatant containing the cytosol and non-nuclear membranes (referred to as cytosol in the Figures) was recentrifuged to remove any residual nuclei. Equal cell equivalents (4i10& cells) of soluble and nuclear fractions were subjected to electrophoresis on SDS\6 % (w\v) polyacrylamide gels, and Western blotting was performed as described below.
Western blots
Cells were treated as indicated in the Figure legends ; control cells received DMSO as a vehicle control. For control and ionomycintreated lysates, cells were left untreated or treated with 2 µM ionomycin for 10 min at 37 mC respectively. After treatment the cells were washed with ice-cold PBS and resuspended in 40 mM Tris\HCl, pH 7.5, containing 10 mM EDTA and 60 mM sodium pyrophosphate. SDS was added to bring the final concentration to 5 % (w\v). Alternatively, the cells were lysed directly into Laemmli buffer. The sample was boiled for 15 min and 4i10& cell equivalents were subjected to electrophoresis on an SDS\6 % polyacrylamide gel. Western blot analysis was performed as described by using affinity-purified NFAT p antibody [15] , and detection was by the enhanced chemiluminescence system. For PKC Western blots, cell lysates (2.5i10& cell equivalents) or fractions (4i10& cell equivalents) were subjected to electrophoresis on SDS\10 % polyacrylamide gels and blotted as above with PKC isoform-specific monoclonal antibodies and sheep anti-(mouse IgG) conjugated to horseradish peroxidase (Amersham).
Withdrawal of ionomycin
For ionomycin withdrawal experiments, cells were treated in bulk with 2 µM ionomycin for 10 min at 37 mC, pelleted and then resuspended in ice-cold PBS. The cells were then split into a separate tube for each treatment and pelleted. The cell pellet was then resuspended at 2i10& cells\ml in complete growth medium at 37 mC. For experiments involving kinase inhibitors, DMSO (vehicle control) or kinase inhibitor was added to the growth medium before resuspension.
RESULTS
Effects of kinase inhibitors on NFAT p phosphorylation and localization
In our previous studies with HT-2 cells we demonstrated that the phosphorylation state of NFAT p is a predictor of its cellular localization : phosphorylated NFAT p is cytosolic, whereas dephosphorylated NFAT p is localized to the nucleus [15] . These results suggest that the net activity of kinases and phosphatases determines the location as well as the phosphorylation state of NFAT p . CaN has been shown to dephosphorylate NFAT p but the identity of the NFAT p kinase(s) is not known. To identify potential pharmacological tools useful in characterizing the NFAT p kinase(s), we treated HT-2 cells with various kinase inhibitors followed by cellular fractionation and Western blotting for NFAT p . We previously established in $#P-labelling experiments [15] that phosphorylated and dephosphorylated NFAT p can be distinguished on the basis of the marked change in mobility under SDS\PAGE that accompanies dephosphorylation ( Figure 1 , arrows). The kinase inhibitors were chosen to target different enzyme specificities, including tyrosine kinases (B46) and serine\threonine kinases, including calmodulin-dependent kinase (KN93), cAMP-dependent kinase (H-89), cGMPdependent protein kinase (KT5823), myosin light-chain kinase (KT5926) and protein kinase C (St and BI). Inhibitors were used at 10 µM, a concentration that has been shown to be effective in other studies on intact cells [18] . As previously observed, in untreated cells NFAT p is phosphorylated and resides in the cytosol. Surprisingly, treatment of the unactivated HT-2 cells with either St or BI, but with none of the other kinase inhibitors, resulted in the dephosphorylation of NFAT p ; the dephosphorylated NFAT p was localized to the nucleus ( Figure 1A ). The effect of St was complete, i.e. no detectable NFAT p remained in the cytosol after treatment with St. Treatment with BI resulted in nuclear localization of the majority of NFAT p ; however, a small but detectable level of dephosphorylated NFAT p remained in the cytosol. Staurosporine (St) inhibits serine\threonine kinases and has a limited specificity for PKC. BI is an St analogue that shows specificity for PKC (K i 0.01 µM) ; however, the concentration used here, 10 µM, is also above the IC &! values for the inhibition of other kinases (IC &! values of 0.7 µM for phosphorylase kinase, 2.0 µM for protein kinase A) [19] . Thus these results are consistent with the hypothesis that one or more serine\threonine kinases, possibly PKC, is involved in phosphorylating NFAT p . Importantly, the results also clearly demonstrate that the kinase(s) is\are critical in maintaining NFAT p in its phosphorylated, cytosolic form, even in unactivated cells.
Inhibition by FK506 of St-induced NFAT p dephosphorylation and localization
In the presence of St or BI, NFAT p was dephosphorylated, suggesting that a basal level of cellular phosphatase activity
Figure 1 Treatment of HT-2 cells with BI and St results in the dephosphorylation and nuclear localization of NFAT p
HT-2 cells were treated, and low-speed supernatant (referred to as cytosol) and nuclear fractions were prepared and Western blotted as described in the Materials and methods section. Western blots of cytosol (upper panels) and nuclei (lower panels) are shown. Lanes 1 and 2 contained cell lysates of untreated and ionomycin-treated cells respectively as controls. The heavy arrow indicates the phosphorylated form of NFAT p ; the light arrow indicates the dephosphorylated form. The kinase inhibitors were used at 10 µM, FK506 at 500 nM and ionomycin at 2 µM. exists in opposition to kinase activity. To determine whether CaN could account for the phosphatase activity in unactivated cells, HT-2 cells were treated with a combination of FK506, 
Effects of kinase inhibitors on the cytoplasmic re-localization of NFAT p
The inhibitor experiments demonstrated that kinase activity regulates NFAT p translocation to the nucleus from the cytosol. A potential role of kinase activity in regulating NFAT p transit from the nucleus back into the cytosol was investigated. Cells were treated with ionomycin, which causes the nuclear localization of NFAT p , followed by washout and resuspension in complete medium containing the same kinase inhibitors used in the experiment of Figure 1 (Figure 2 ). After incubation for 45 min, the cellular localization of NFAT p was measured. Removal of ionomycin and resuspension of the cells in medium alone results in the reappearance of NFAT p in the cytosol (Figure 2 , lane 4) [15] . Furthermore, the cytosolic NFAT p was exclusively in the phosphorylated form. In cells treated with either 10 µM BI or St, NFAT p cytosolic accumulation was blocked and NFAT p remained in the nucleus in a dephosphorylated state. Complete inhibition was observed with 10 µM St, whereas 1.0 µM St partly inhibited, and 0.1 and 0.01 µM St did not block nuclear export (Figure 3) . BI inhibited significantly, but not completely, because in the BI-treated cells some dephosphorylated NFAT p was also detected in the cytosol at 45 min. As with NFAT p localization to the nucleus, none of the other kinase inhibitors had any effect on NFAT p reaccumulation in the cytosol after ionomycin removal. These results demonstrate that the reaccumulation in the cytosol and rephosphorylation of NFAT p are clearly inhibited by St and BI. Furthermore, they establish that kinase activity regulates NFAT p when it is in both the cytosolic and nuclear compartments.
Expression and distribution of PKC isoforms
Our experiments indicate that one or more serine\threonine kinase(s) are involved in NFAT p phosphorylation, but little 1 and 3) or ionomycin (I) (lanes 2 and 4), washed with PBS and fractionated into non-nuclear (cyt) (lanes 1 and 2) or nuclear (nuc) (lanes 3 and 4) fractions. Aliquots were Western blotted with isoenzyme-specific PKC antibodies. (B) Cells were treated with 500 nM PMA for 72 h (P, lane 2) or left untreated (C, lane 1). Cells were washed with PBS and lysed, and aliquots were Western blotted with isoenzyme-specific PKC antibodies. PKCα, ε and θ levels also were down-regulated (results not shown). (C) HT-2 cells were treated with 500 nM PMA for 72 h or left untreated (control). Cells were then treated with ionomycin, washed with PBS and resuspended in growth medium. Cells were removed at the indicated time points, fractionated into a non-nuclear low-speed fraction (cytosol) and nuclei, and then Western blotted as described in the Materials and methods section. Lanes 1 and 2 contained cell lysates of untreated and ionomycin-treated cells respectively as controls.
Figure 4 PMA treatment of HT-2 cells does not inhibit NFAT p nuclear export (A) HT-2 cells were treated with DMSO [control (C)] (lanes
additional information is known about the kinase(s). Because St and BI both inhibit PKC, and PKC is involved in T-cell activation, we investigated a possible role for PKC in regulating the NFAT p phosphorylation state. PKC isoenzyme expression was characterized in HT-2 cells by using Western blot analysis and isoenzyme-specific antibodies ( Figure 4A) . Localization of the isoforms was also examined, because differences exist in their cellular locales [20] [21] [22] [23] [24] . Seven different PKC isoforms were expressed, including α, δ, ε, ζ, θ, ι and µ. All of the isoenzymes, with the exception of ζ, were localized to the non-nuclear fraction ; treatment of the cells with ionomycin did not alter this localization ( Figure 4A ). In contrast, PKCζ was expressed in both the non-nuclear and nuclear fraction of the cells under both untreated and ionomycin-treated conditions.
Effect of down-regulation of PKC by PMA on NFAT p localization
To investigate a possible role for PKC in NFAT p phosphorylation, PKC levels were down-regulated by PMA treatment. Cells were treated with 500 nM PMA for 72 h, which resulted in the disappearance of the PMA-sensitive PKC isoforms α, δ, ε and θ from the cells, as shown by Western blot analysis ( Figure 4B , and results not shown). No change in the level of the three PMA-insensitive PKC isoforms ζ, ι and µ was detected, as expected. No change in the cytosolic accumulation of phosphorylated NFAT p after ionomycin washout was observed between control and cells down-regulated by PMA ( Figure 4C ). Although these results do not rule out the involvement of one of the PMA-insensitive PKC isoforms in nuclear export and rephosphorylation, they suggest that a PMA-sensitive isoform of PKC is not involved in these processes.
Effect of low temperature on the cytosolic reaccumulation of NFAT p
NFAT p was localized to the nucleus after kinase inhibition (by St) or CaN activation (by ionomycin). Conversely, ionomycin washout, or addition of FK506 after ionomycin treatment, resulted in the reaccumulation of NFAT p in the cytosol. The 120 kDa NFAT p is above the limit for diffusion through nuclear pores, suggesting an active export mechanism [25, 26] . To determine whether NFAT p reaccumulation in the cytosol is an active process, temperature experiments were performed. Ionomycin-treated cells were washed and resuspended in complete growth medium at either 37 or 4 mC ( Figure 5 ). NFAT p remained in the nucleus in the chilled cells throughout the 120 min time course, whereas at 37 mC export was complete within 30-60 min. Throughout the temperature experiments the viability of the cells, as measured by Trypan Blue exclusion, was not affected (results not shown). These results demonstrate that the reaccumulation of NFAT p into the cytosol is temperaturedependent, consistent with an active export process.
DISCUSSION
Our results demonstrate that in both activated and unactivated T-cells, the steady-state level of NFAT p phosphorylation is determined by a dynamic equilibrium between CaN and cellular kinases. In resting cells, inhibiting kinase activity with St resulted in unopposed CaN phosphatase activity, leading to a net dephosphorylation of NFAT p . Addition of FK506 to inhibit CaN blocked the St effect, demonstrating the regulatory role of CaN. In activated cells CaN is activated directly by ionomycin treatment, also resulting in a shift in the kinase-CaN equilibrium. These results are consistent with a model in which NFAT p is constantly undergoing dephosphorylation and rephosphosphorylation with the net effect, in resting cells, of a phosphorylated, cytoplasmic NFAT p . The concept that the level of phosphorylation is the net result of kinase and phosphatase activities is not novel. However, our results focus on the role of kinases in regulating NFAT p ; our results also emphasize that there is a basal level of CaN and kinase activity in resting cells.
Evidence from previous work by us and others [14, 15, 17] , as well as the results shown here, indicate that NFAT p cellular localization depends on its phosphorylation state. Dephosphorylation of NFAT p by treatment with either St or ionomycin results in nuclear localization of NFAT p . As recently suggested by Shibasaki et al. [27] , CaN might also co-localize with NFAT to the nucleus. In cells washed free of ionomycin, NFAT p is rephosphorylated and relocalized in the cytoplasm. The mechanism by which dephosphorylation results in nuclear localization is not known. However, at least one putative nuclear localization sequence (NLS) has been identified in NFAT p within the C-terminal region of the Rel homology domain [7] . Dephosphorylation of sites at or near the NLS, either by kinase inhibition or CaN activation, might unmask the NLS, allowing nuclear import of NFAT p . Similar mechanisms have been identified for other transcription factors, such as v-Jun, in which phosphorylation of a serine adjacent to the NLS negatively regulates nuclear import [28, 29] .
Energy depletion and decreased temperature are known to block both nuclear import and export [30] [31] [32] [33] [34] . Our results indicate that the accumulation of NFAT p from the nucleus into the cytosol also was blocked under low-temperature conditions, consistent with the nuclear export of NFAT p as an active process. However, our results also demonstrate that St and BI block NFAT p transit from the nucleus. Kinase activity also might be inhibited under the lower-temperature conditions. Thus the low temperature might be blocking the export process directly, as well as the NFAT p kinase, resulting in the net effect of blocking the reaccumulation of NFAT p in the cytosol.
Protein import into the nucleus has been studied in permeabilized cells by using model proteins, allowing the characterization both of factors required for import and of the nuclear pore complex itself [25, 26, 34, 35] . Less is known about protein nuclear export, although it utilizes the same pore complex [36] . Active export of several proteins has been characterized, including the protein heat-stable inhibitor (PKI) of cAMP-dependent kinase [26, 37, 38] . PKI contains a nuclear export sequence (NES) that stimulates rapid export of the PKI-protein kinase A complex [20] . Comparison of the PKI NES with the NES of HIV-1 Rev and TFIIIA has suggested a loose consensus sequence for nuclear export that is rich in leucine and other hydrophobic
Scheme 1 Dynamic equilibrium model of NFAT p phosphorylation state and nuclear/cytoplasmic cycling
In resting and activated cells NFAT p is constantly being dephosphorylated by CaN and re-phosphorylated by one or more kinases. In resting cells the equilibrium is shifted in favour of phosphorylated NFAT p ; in activated cells the CaN activity is increased, shifting the equilibrium to dephosphorylated NFAT p , which is imported into the nucleus. Dephosphorylated NFAT p in the nucleus is constitutively exported from the nucleus. In the continuing presence of ionomycin (or antigen), CaN activity is maintained and NFAT p is kept dephosphorylated and imported back into the nucleus. If ionomycin or antigen is withdrawn, CaN activity returns to its basal activity level and kinase activity results in the net re-phosphorylation of NFAT p , which is retained in the cytoplasm.
residues with conserved spacing between hydrophobic residues [37] . A similar export sequence might exist in NFAT p . In fact, NFAT p contains the sequence LKLRNADIEL, corresponding to residues 521-530, which is homologous with the PKI NES, LALKLAGLDI, if homologous substitutions are allowed. The underlined amino acids in the PKI NES indicate residues that have been identified by mutagenesis as particularly important for nuclear export [20] . By homology comparison between different NESs, it seems that I and L can be substituted for each other at important sites. Of course, any role that this sequence might have in NFAT p nuclear export will need to be experimentally determined.
The identities of the kinases involved in NFAT p phosphorylation and\or nuclear export are not known. The broadspecificity tyrosine kinase inhibitor B46 had no effect ; neither did a number of other serine\threonine kinase inhibitors. However, both St and BI showed activity, and both these compounds inhibit serine\threonine kinases, with particular specificity in itro for PKC. We investigated a potential role for PKC in NFAT p phosphorylation. Down-regulation of PKC levels results from prolonged treatment with PMA and is a useful method to investigate a potential role of PKC in cellular responses. Three of the PKC isoforms expressed in HT-2 cells are PMA-sensitive (α, δ and ε) and thus are able to be down-regulated, whereas four are PMAinsensitive (ζ, θ, ι and µ) [23, 39, 40] . In the down-regulated cells, no differences were detected in the cytosolic accumulation and phosphorylation of NFAT p after ionomycin removal. These results suggest that none of PKC α, δ, or ε are involved in NFAT p phosphorylation, but they do not rule out a potential role for the PMA-insensitive isoforms (ζ, θ, ι and µ). Furthermore, because of the lack of absolute specificity of St and BI, other serine\ threonine kinases instead of, or in addition to, PKC might be the NFAT p kinase. Our fractionation experiments indicate that NFAT p phosphorylation occurred in the cytosol and not in the nucleus. Under all of our treatment conditions little or no phosphorylated NFAT p was detected in the nucleus, suggesting that the NFAT p kinase(s) reside in the cytosol. Complete identification of the kinase(s) as well as their cellular localization will require further biochemical studies.
Taken together, these results are consistent with the model shown in Scheme 1. NFAT p is present in the cytosol of the cells in a predominantly phosphorylated state. The net state of phosphorylation results from a dynamic equilibrium between CaN and the NFAT p kinase(s). Changes in this equilibrium, either through CaN activation or kinase inhibition, result in dephosphorylated NFAT p . The dephosphorylation of NFAT p seems to serve as a signal for nuclear import, possibly by unmasking a nuclear localization sequence. Nuclear export of NFAT p fits the requirements of an active, energy-requiring process that might occur constitutively, possibly through an NES sequence on NFAT p . In this model, dephosphorylated NFAT p that is exported back into the cytosol after the withdrawal of ionomycin would be rephosphorylated by the NFAT p kinase(s). However, as shown in Figure 2 , kinase inhibition by St prevents the constitutively exported NFAT p from being rephosphorylated ; it is therefore rapidly re-imported into the nucleus, with the net effect that St seems to block nuclear export.
Constitutive cycling of NFAT p proposed in this model provides a simple mechanism consistent with the results that in the continuing presence of ionomycin, FK506 induces a complete reversal of the nuclear localization and dephosphorylation of NFAT p (Figure 1 ) [14] . This model suggests that in the continuing presence of ionomycin (or antigen stimulation), CaN activity is required for maintaining a net accumulation of dephosphorylated NFAT p in the nucleus by continually dephosphorylating exported NFAT p , which would then be re-imported into the nucleus. An inhibitor of CaN activity such as FK506 would block dephosphorylation and would allow exported NFAT p to be phosphorylated by NFAT p kinase(s) and therefore retained in the cytoplasm rather than re-imported. Such a simple nuclear\ cytoplasmic cycling mechanism would allow the cell to adjust NFAT p transcriptional activating activity continually to changing CaN activity levels, which in turn reflect changing antigen exposure.
Clearly there are aspects of this model that require further experimental validation. For example, it is not clear from our experiments whether nuclear export itself requires kinase activity. Similarly, whether NFAT p nuclear export occurs constitutively is not known. However, the results shown here demonstrate clearly that a kinase(s) and the phosphatase CaN act in concert to determine both the phosphorylation state and the cellular localization of NFAT p .
